Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12278 Scripps Summit Drive SAN DIEGO CA 92131 |
Tel: | N/A |
Website: | https://fatetherapeutics.com |
IR: | See website |
Key People | ||
John Scott Wolchko President, Chief Executive Officer, Director | Edward J. Dulac Chief Financial Officer | Cindy R. Tahl General Counsel and Corporate Secretary |
Brian T. Powl Chief Commercial Officer | Bahram Valamehr Chief Research and Development Officer |
Business Overview |
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company's platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Fate Therapeutics Inc revenues decreased 34% to $63.5M. Net loss decreased 43% to $160.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research & Development decrease of 44% to $151.7M (expense), Stock-based Compensation in R&D decrease of 59% to $20.8M (expense). |
Employees: | 181 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $122.81M as of Dec 31, 2023 |
Annual revenue (TTM): | $63.53M as of Dec 31, 2023 |
EBITDA (TTM): | -$172.23M as of Dec 31, 2023 |
Net annual income (TTM): | -$160.93M as of Dec 31, 2023 |
Free cash flow (TTM): | -$138.42M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 113,172,530 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |